Kincell Bio Announces New Board Chairman Mark R. Bamforth to Accelerate Company’s Growth and Expansion
May 21 2024 - 7:00AM
Kincell Bio, LLC (“Kincell”), a technology-forward contract
development and manufacturing organization (CDMO) focused on cell
therapies, today announced the appointment of Mark R. Bamforth as
the Company’s new Board Chairman. This strategic appointment
further strengthens Kincell’s position as the Company continues to
expand its capacity to provide high-quality support for the cell
therapy market. Mr. Bamforth will replace the current Board
Chairman, Shailesh Maingi, who will remain on the Board.
“In advanced biopharmaceutical manufacturing, Mark has a
demonstrated ability to scale best-in-class CDMOs with high
performing teams that have been market leaders in the cell and gene
therapy, microbiome and monoclonal antibody sectors,” said Mr.
Maingi. “As he takes on the role of Board Chairman at Kincell, his
wealth of experience and strategic vision plus his commitment to
scientific excellence, has the potential to propel the Company to
new heights and to deliver cell therapies to clients and their
patients.”
A serial entrepreneur with decades of experience building value
in biotech, Mr. Bamforth has founded, built and sold three CDMOs.
He currently invests in and mentors U.S.- and Scottish-based life
science entrepreneurs in addition to serving as a general partner
in an antimicrobial resistance fund. In May 2019, Mr. Bamforth
founded Arranta Bio, an advanced therapeutics CDMO focused on the
microbiome, plasmid and mRNA vaccines, which was sold to Recipharm
in April 2022. Prior, he founded Brammer Bio, a best-in-class viral
vector CDMO for cell and gene therapies that supported leading
innovators. Brammer’s team grew six-fold, reaching over 600
employees at the time of its acquisition by Thermo Fisher
Scientific in April 2019. In 2010, Mr. Bamforth founded a biologics
CDMO, Gallus BioPharmaceuticals, and acquired a world-class
facility and team with a commercial supply agreement with Janssen.
The Company tripled through organic growth and merged with Laureate
Biopharma, before being sold to DPx Holdings (Patheon) in 2014. Mr.
Bamforth spent 22 years at Genzyme, with nearly a decade as a
corporate officer leading the Company’s 12-site global
manufacturing operation and a pharmaceutical CMO unit. He serves on
the boards of Continuus Pharma, Pneumagen, Enterobiotix and
Entrepreneurial Scotland. Mr. Bamforth has a BS in Chemical
Engineering from Strathclyde University and an MBA from Henley
Management College.
“I’m excited to leverage my experience to help guide the
leadership team at Kincell as they continue expanding Kincell’s
cell engineering footprint in the delivery of transformative
healthcare solutions for clients. The Company’s dedication to
innovation, process development and manufacturing excellence
resonates deeply with me,” said Mr. Bamforth. “Together, we will
accelerate the adoption of our clients’ cell therapies, harnessing
the power of cutting-edge technology to revolutionize patient care
through personalized medicine.”
About Kincell BioKincell Bio, LLC (“Kincell” or
the “Company”) engineers cells into therapies. The Company is a
technology-forward contract development and manufacturing
organization (CDMO) formed to streamline analytical development,
process development, CMC consulting and GMP manufacturing for
cellular therapies. With facilities in Gainesville, Fla. to support
early clinical supply production and in Research Triangle Park,
North Carolina with a phase II/III facility to support late-stage
development, Kincell’s focus is on the development and
manufacturing of immune cell therapies, including autologous and
allogeneic CAR-T, CAR-NK and CAR-M programs for clients. For more
information, visit www.kincellbio.com.
Media Contact Gina Mangiaracina6 DegreesEmail:
gmangiaracina@6degreespr.com